---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-410781"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2026-10-01T20:49:37+00:00"
generated_at: "2026-10-12T14:26:04.708675+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences appoints Benjamin Halladay CFO effective Oct. 5, 2026; Mark Oki steps down

## Summary
- Benjamin Halladay appointed CFO and principal financial officer effective Oct. 5, 2026; he was most recently CFO of Esperion Therapeutics from Nov. 2022 to Sept. 2026.
- Halladay's compensation includes a $525,000 annual base salary, a discretionary bonus up to 40% of salary, 200,000 stock options and 200,000 RSUs.
- Mark Oki stepped down as CFO effective Oct. 5, 2026; the company said his departure was not due to disagreement over financial statements or disclosures.
- Halladay severance: nine months of base salary, or 12 months plus prorated bonus and accelerated option/RSU vesting if tied to a change in control.
- Oki will receive severance under his Executive Employment Agreement dated Dec. 5, 2024, filed as Ex. 10.19 to the company's 2024 Form 10-K.

## SEC filing metadata
- accession: 0001193125-26-410781
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2026-10-01T20:49:37+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000119312526410781/0001193125-26-410781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000119312526410781/achv-20261001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-410781
- JSON: https://secwatch.observer/filing/0001193125-26-410781.json
- Plain text: https://secwatch.observer/filing/0001193125-26-410781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.